Work

Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps9105

Authors: Paolo Antonio Ascierto, Keith Flaherty, Paola Queirolo, Ryan J. Sullivan, Vanna Chiarion-Sileni, Ruggero Ridolfi, Alessandro Testori, Ester Simeone, Antonio Maria Grimaldi, Francesco Sabbatino, Marcello Curvietto, Gennaro Ciliberto, Gerardo Botti, Nicola Mozzillo, Soldano Ferrone

Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Harvard University, Massachusetts General Hospital, Istituto Oncologico Veneto, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, European Institute of Oncology

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2248665988

Cites:

Cited by: 3

Related to: 10